UBS AM’s AN2 Therapeutics ANTX Stock Holding History

UBS AM’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-76,200	Closed	-$248K	–	2802
2024 Q1	$248K	Buy	+76,200	New	+$829K	﹤0.01%	2433

Other funds holding ANTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM's ANTX Position: Q2 2024 in Review

UBS AM sold out of AN2 Therapeutics (ANTX) in Q2 2024, closing a stake of 76,200 shares — an estimated $248K sold.

UBS AM first reported a position in ANTX in Q1 2024 and held it in 1 quarter. The position peaked at $248K in Q1 2024. 45 funds tracked by Wall St. Rank hold ANTX as of Q2 2024.

UBS AM reported no remaining AN2 Therapeutics position as of Q2 2024 after selling out during the quarter.
UBS AM sold 76,200 AN2 Therapeutics shares in Q2 2024, an estimated $248K.
UBS AM first reported a position in AN2 Therapeutics in Q1 2024 and held it in 1 quarter.
UBS AM's AN2 Therapeutics position peaked at $248K in Q1 2024.
45 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2024.

Based on UBS AM's 13F filing for Q2 2024, filed 14 Aug 2024.